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THE KOREAN INDIVIDUAL-MICROSIMULATION MODEL FOR
CARDIOVASCULAR HEALTH INTERVENTIONS (KIMCHI)
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OBJECTIVES: To develop an epidemiological and economic
model of ﬁrst-onset cardiovascular disease (CVD, comprising
myocardial infarction and ischemic stroke) in Korea that can
be applied to cost-effectiveness analyses of interventions.
METHODS: KIMCHI is a Markov model with yearly cycles and
the health states ‘Alive without CVD’, ‘Alive with CVD’, ‘Dead
from CVD’ and ‘Dead from non-CVD causes’. It is populated
with 5270 CVD-naïve subjects aged 18 years from the 2005
Korea National Health and Nutritional Examination Survey.
Annual probabilities of CVD are estimated for each individual
using the Asian-speciﬁc risk equation by Wu, the covariates for
which are: sex, age, total cholesterol (TC), systolic blood pres-
sure (SBP), smoking, diabetes and body mass index (BMI). Age-
and-sex-speciﬁc annual probabilities of death are based on
national health data. To illustrate the function of KIMCHI,
follow-up was simulated of Koreans aged 55 years until death
or age 99 and the cost-effectiveness of atorvastatin for the
primary prevention of CVD assessed using decision analysis. The
TC-reducing efﬁcacy and cost of atorvastatin were drawn from a
meta-analysis and current drug pricing schedules, respectively.
CVD costs were provided by the Korean Health Insurance
Review and Assessment Services. A 5% annual discount rate was
applied. RESULTS: KIMCHI predicted that 30.4% and 18.2%
of CVD-naïve Koreans currently aged 55 years will develop
non-fatal and fatal CVD, respectively, by age 99. Atorvastatin
was predicted to reduce these ﬁgures to 25.4% and 15.4%,
corresponding to numbers needed to treat of 20 and 36 to
prevent non-fatal and fatal CVD, respectively. The estimated
ICERs were 21.8 million KW/YoLS and 17.4 million KW/QALY
saved. CONCLUSIONS: KIMCHI is a contemporary epidemio-
logical and economic model of CVD in Korea that can predict
future patterns of disease and be applied to cost-effectiveness
analyses of interventions that alter any of TC, SBP, smoking,
diabetes and BMI.
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COST EFFECTIVENESS OF HIGH DOSE ATORVASTATIN IN
ACUTE CORONARY SYNDROME PATIENTS INTHE UK
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OBJECTIVES: To estimate the long- and short-term costs and
effects of 2 year treatment with high-dose atorvastatin (80 mg)
versus medium dose simvastatin (40 mg) in patients with acute
coronary syndrome (ACS) and to analyse risk levels where
therapy may be expected to be cost-effective. METHODS: Efﬁ-
cacy is estimated based on a preliminary Bayesian meta-analysis
linking decrease in LDL cholesterol levels to decreases in sec-
ondary cardiac events (MI, stroke, cardiovascular death)
drawing data from the A to Z and PROVE-IT trials and using
priors from other statin trials. The Markov model combines
estimates of the occurrence of later events; UK cost data; and
quality of life. A baseline risk of 12% is taken from the CURE
trial, an ACS study with risks that lie between those in the
international ACS registry (GRACE) and those of the two
statin trials. RESULTS: At a 12% event risk during the ﬁrst 6
months and a 4% risk during later months, and with an esti-
mated 10% additional efﬁcacy of high-dose atorvastatin, the
estimated NNT to avoid one event is approximately 50. Costs
per life year gained and costs per QALY are estimated at below
£10,000. Costs per QALY are anticipated to be over £30,000
when the 6-month risk of cardiac events is less than 1% (cor-
responding with a 10-year risk of >20%), or when the esti-
mated additional risk reduction due to high-dose atorvastatin is
less than 3%. CONCLUSIONS: Based on our preliminary ﬁnd-
ings, high-dose atorvastatin is estimated to be cost-effective in
comparison to medium dose simvastatin in ACS patients. As
the analysis presented here is preliminary, the results may alter
following reconsideration of the priors. In addition, subsequent
probabilistic analysis will be used to explore uncertainties
around the estimates.
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ANEURYSM OCCLUSION IN ELDERLY PATIENTS WITH
ANEURYSMAL SUBARACHNOID HAEMORRHAGE:
A COST-UTILITY ANALYSIS
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OBJECTIVES: To determine the balance between risks and ben-
eﬁts of aneurysm occlusion in elderly patients with subarachnoid
haemorrhage (SAH), as function of patient characteristics and
aneurysm characteristics. The analysis focused mainly on the
effects of patient age, clinical condition and day of admission
after SAH. METHODS: With Markov model Monte Carlo simu-
lation we evaluated health gains, in quality-adjusted life years
(QALY), additional costs, and incremental cost-effectiveness
ratios (ICER) of aneurysm occlusion in 192 subgroups of
patients. Subgroups were deﬁned by age (70–74, 75–79, 80–84,
85+ years), neurological condition at admission (poor or good),
day of admission after SAH (<4, 4–10, 11–21 days), gender,
aneurysm size (<10 mm or 10 mm) and aneurysm location
(anterior or posterior circulation). RESULTS: In patients admit-
ted in poor condition 10 days after SAH, and patients older
than 80 years, admitted in poor condition 4 days after SAH,
aneurysm occlusion implied QALY loss as well as increased costs,
regardless of aneurysm size and location. The ICER of occlusion
was better than €50,000/QALY only in women aged 70–79
years, and men aged 70–74 years, admitted in good condition in
<4 days. Occlusion was both beneﬁcial and cost-saving in women
aged 70–74 years, admitted in good condition in <4 days, with a
small posterior aneurysm. CONCLUSIONS: Occlusion of rup-
tured intracranial aneurysms instead of conservative treatment
improves outcome in some elderly patients, but not in all, and
will often incur unacceptably high costs. The occlusion beneﬁts
of reduced risks of rebleeding and recurrent SAH only ensure the
ﬁnal balance is positive when patients can proﬁt from them, in
fair health, over several years. Thus, beyond some patient age,
occlusion should no longer be viewed as standard treatment,
but as option, viable only in patients with a prolonged life
expectancy.
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OBJECTIVES: Hypertension is a major risk factor for cardio-
vascular disease and a leading cause of morbidity and mortality.
The present study evaluates irbesartan in relation to losartan
and valsartan in the treatment of hypertension in Greece.
METHODS: A Markov model was constructed with eight health
states, including: hypertension, myocardial infarction, post-MI,
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angina, stroke, post-stroke, heart failure and death. It has an
annual cycle and estimates mean quality-adjusted survival and
treatment cost, which reﬂects hypertension treatment and the
management of cardiovascular events. Risk functions were used
to conduct extrapolations. Data on treatment effectiveness,
quality-of-life and epidemiology were obtained from published
clinical trials and studies. The database of the main insurance
fund (IKA) was analysed to estimate the cost of events. The
analysis was done from a payer perspective, all outcomes were
discounted at 3% and prices correspond to 2008. RESULTS: The
estimated patient cost per annum for each health state was: stable
angina: €2252; unstable angina: €2572; myocardial infarction:
€2473; post-MI: €1677; stroke: €12,233; post-stroke: €1240;
heart failure: €2655; angiogram: €1544; angioplasty: €6511;
bypass surgery; €11,514. For the baseline group (age: 57 years,
systolic-blood-pressure: 147, cholesterol: 6.00 mmol/L, BMI:
29 kg/m2) with mild/moderate disease, the total cost was €15,146
with irbesartan, €15,486 with losartan and €15,613 valsartan;
QALYs were 12.67, 12.63 and 12.64, respectively. For the group
with severe disease, the total cost with irbesartan) was €15,798
(150 mg) and €18,697 (300 mg), whilst with Losartan was
€16,295 (50 mg) and €22,496 (100 mg); QALYs were 12.47 and
12.37 for irbesartan and losartan respectively. Thus, irbesartan
was less costly and more effective and dominated the other two
treatments. Similar results were obtained in relation to various
other patient groups and several sensitivity analyses. CONCLU-
SIONS: For different patient populations, irbesartan represents
good value for money in the Greek NHS setting, compared to
selected commonly used alternatives.
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TISSUE ENGINEERING OFVALVEDVENOUS CONDUITS (VVC)
VERSUS CONSERVATIVETHERAPY IN PATIENTS WITH
CHRONICVENOUS INSUFFICIENCY (CVI). A DECISION
ANALYTIC MODEL USING EXPERT ESTIMATED UTILITIES
BASED ON DERIVED DATA FROM ANIMAL STUDIES AS A
PRE-MARKETINGTECHNOLOGY ASSESSMENT APPROACH
WITH GERMAN DATA
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OBJECTIVES: The development of a decision model for the
assessment of the emerging technology implantation of valved
venous conduits (VVC) using tissue engineering in patients with
chronic venous insufﬁciency (CVI) versus Conservative treatment
options like horse chestnut seed extract and compression therapy.
METHODS: The model allows to enter parameters for the efﬁ-
cacy, safety, long-term effectiveness, quality of life, disease-speciﬁc
mortality, and costs and to derive (quality-adjusted) life expect-
ancy and cost-effectiveness from a health care system perspective.
It evaluates a lifelong time horizon using the Gompertz function
and applies an annual discount rate of 3%. Cost and epidemio-
logical data of CVI were gathered from literature. The costs for
VVCwere estimated considering the development costs. Finally to
calculate QALYs we surveyed a panel of angiologists and angio-
surgeons presenting the results of animal studies concerning the
functionality, tolerability and hemorheology. RESULTS: A mar-
ginal difference of 0.04 LY in favor of VVC was calculated
incorporating the lethality of the implantation. VVC yielded
additional QALY gains of 2.02 compared to conservative therapy.
Patient implanted with VVC were estimated to reach a utility of
0.64 comparedwith 0.50 for those receiving conservative therapy.
VVC was in the conservative scenario with implantation of up to
four conduits €4395 more expensive; in the scenario with up to
two implanted conduits the difference was only €330. VVC seems
to be cost-effective for CVI patients, with an incremental cost-
effectiveness ratio compared with conservative therapy of 163 to
€2176/QALY. CONCLUSIONS: Especially in the ﬁeld of emerg-
ing technologies, where data from clinical trials are lacking,
decision-analytic modeling even in a pre-market condition is a
useful tool to systematically assess the expected value of technolo-
gies and the related uncertainty. Thereby, developers can avoid
misdirected investment in health care systems ruled by thresholds
even before the diffusion of a technology.
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AN ECONOMIC EVALUATION OFTHE ADDITION OF
FIXED-DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN
THERAPYTOTHE MANAGED CARE FORMULARY INTERMS
OF OPTIMAL LIPIDVALUE ATTAINMENT
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OBJECTIVES: To model the impact of the addition of ﬁxed-dose
niacin extended-release and simvastatin (NER/S) therapy to a
health plan formulary in terms of optimal low density lipoprotein
cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-
C), and triglyceride (TG) value attainment. METHODS: Two
hypothetical formularies with all major branded and generic lipid
drugs were modeled over a three year time horizon: a formulary
not including NER/S (current formulary) and a formulary which
did (revised formulary). Primary and secondary risk patients with
1 sub-optimal lipid parameter were sampled from the Health-
Core Integrated Research Database between 1/1/2000 and 2/28/
2005. Package insert efﬁcacy of antihyperlipidemic medications
in each formulary was applied to the sample population. Post-
treatment lipid values were evaluated according to U.S. lipid
guidelines. Rates of individual and combined optimal lipid value
(OLV) [LDL-C, HDL-C, and TG] achievement were estimated in
direct proportion to lipid therapy market shares in both formu-
laries. Changes in clinical outcomes between formularies were
evaluated relative to incremental change in pharmacy and car-
diovascular (CV) disease related medical costs. Market penetra-
tion of NER/S was assumed to be 1.5% and payer discounts of
17% and 50% were applied to branded and generic wholesale
acquisition costs. RESULTS: The rate of combined OLV attain-
ment over three years in the revised formulary increased 0.57%
from the current formulary. Attainment of optimal LDL-C,
HDL-C and TG values increased by 0.07%, 0.30%, and 0.10%,
respectively. The cost for a 1% increase in optimal LDL-C,
HDL-C, and TG attainment was $3103, $952, and $2047
respectively. There was an estimated $1147 cost for every 1%
increase in combined OLV attainment. CONCLUSIONS: The
addition of NER/S to the health plan formulary increases indi-
vidual and combined OLV achievement thereby having the
potential to reduce the incidence of CV events and CV-related
medical costs.
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CHANGE IN LIPIDVALUES,TARGET LIPIDVALUE
ATTAINMENT,AND ANNUAL HEALTH CARE RESOURCE
UTILIZATION AND COSTS AMONG PATIENTS INITIATING
COMBINATION STATIN AND EXTENDED-RELEASE
NIACINTHERAPY
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OBJECTIVES: To evaluate changes in low-density lipoprotein
cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-
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